Sanofi India Limited (SANOFI) - Net Assets
Based on the latest financial reports, Sanofi India Limited (SANOFI) has net assets worth Rs7.49 Billion INR (≈ $81.02 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs12.55 Billion ≈ $135.70 Million USD) and total liabilities (Rs5.06 Billion ≈ $54.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SANOFI tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs7.49 Billion |
| % of Total Assets | 59.71% |
| Annual Growth Rate | 2.77% |
| 5-Year Change | -66.34% |
| 10-Year Change | -56.83% |
| Growth Volatility | 15.62 |
Sanofi India Limited - Net Assets Trend (2004–2025)
This chart illustrates how Sanofi India Limited's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Sanofi India Limited to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sanofi India Limited (2004–2025)
The table below shows the annual net assets of Sanofi India Limited from 2004 to 2025. For live valuation and market cap data, see Sanofi India Limited market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Rs7.49 Billion ≈ $81.02 Million |
-12.94% |
| 2024-12-31 | Rs8.61 Billion ≈ $93.07 Million |
-15.23% |
| 2023-12-31 | Rs10.15 Billion ≈ $109.79 Million |
-20.43% |
| 2022-12-31 | Rs12.76 Billion ≈ $137.97 Million |
-42.68% |
| 2021-12-31 | Rs22.26 Billion ≈ $240.69 Million |
+5.03% |
| 2020-12-31 | Rs21.19 Billion ≈ $229.16 Million |
-13.24% |
| 2019-12-31 | Rs24.42 Billion ≈ $264.13 Million |
+10.05% |
| 2018-12-31 | Rs22.19 Billion ≈ $240.00 Million |
+9.51% |
| 2017-12-31 | Rs20.26 Billion ≈ $219.15 Million |
+16.76% |
| 2016-12-31 | Rs17.36 Billion ≈ $187.70 Million |
+6.66% |
| 2015-12-31 | Rs16.27 Billion ≈ $175.97 Million |
+9.51% |
| 2014-12-31 | Rs14.86 Billion ≈ $160.69 Million |
+10.33% |
| 2013-12-31 | Rs13.47 Billion ≈ $145.64 Million |
+11.84% |
| 2012-12-31 | Rs12.04 Billion ≈ $130.22 Million |
+7.84% |
| 2011-12-31 | Rs11.17 Billion ≈ $120.76 Million |
+10.10% |
| 2010-12-31 | Rs10.14 Billion ≈ $109.68 Million |
+8.84% |
| 2009-12-31 | Rs9.32 Billion ≈ $100.77 Million |
+12.39% |
| 2008-12-31 | Rs8.29 Billion ≈ $89.66 Million |
+17.30% |
| 2007-12-31 | Rs7.07 Billion ≈ $76.44 Million |
+16.22% |
| 2006-12-31 | Rs6.08 Billion ≈ $65.78 Million |
+16.12% |
| 2005-12-31 | Rs5.24 Billion ≈ $56.65 Million |
+24.17% |
| 2004-12-31 | Rs4.22 Billion ≈ $45.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sanofi India Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs3.32 Billion | 44.31% |
| Common Stock | Rs230.00 Million | 3.07% |
| Other Components | Rs3.94 Billion | 52.62% |
| Total Equity | Rs7.49 Billion | 100.00% |
Sanofi India Limited Competitors by Market Cap
The table below lists competitors of Sanofi India Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
|
$839.53 Million |
|
Standard Lithium Ltd
V:SLI
|
$839.68 Million |
|
Daheng New Epoch Technology Inc
SHG:600288
|
$839.88 Million |
|
Beijing Asiacom Information Technology Co.Ltd
SHE:301085
|
$839.97 Million |
|
Intelbras S.A. - Indústria de Telecomunicação Eletrônica Brasileira
SA:INTB3
|
$839.46 Million |
|
Veken Elite
SHG:600152
|
$839.24 Million |
|
Shanghai Haohai Biological Tech Co
SHG:688366
|
$839.16 Million |
|
YCC CORP
KQ:232140
|
$839.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sanofi India Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,606,000,000 to 7,492,000,000, a change of -1,114,000,000 (-12.9%).
- Net income of 3,267,000,000 contributed positively to equity growth.
- Dividend payments of 4,422,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 3,898,000,000.
- Other factors increased equity by 3,939,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.27 Billion | +43.61% |
| Dividends Paid | Rs4.42 Billion | -59.02% |
| Other Comprehensive Income | Rs-3.90 Billion | -52.03% |
| Other Changes | Rs3.94 Billion | +52.58% |
| Total Change | Rs- | -12.94% |
Book Value vs Market Value Analysis
This analysis compares Sanofi India Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.40x to 10.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | Rs183.16 | Rs3370.50 | x |
| 2005-12-31 | Rs227.43 | Rs3370.50 | x |
| 2006-12-31 | Rs264.08 | Rs3370.50 | x |
| 2007-12-31 | Rs306.91 | Rs3370.50 | x |
| 2008-12-31 | Rs360.00 | Rs3370.50 | x |
| 2009-12-31 | Rs404.59 | Rs3370.50 | x |
| 2010-12-31 | Rs440.35 | Rs3370.50 | x |
| 2011-12-31 | Rs484.84 | Rs3370.50 | x |
| 2012-12-31 | Rs522.83 | Rs3370.50 | x |
| 2013-12-31 | Rs584.74 | Rs3370.50 | x |
| 2014-12-31 | Rs645.16 | Rs3370.50 | x |
| 2015-12-31 | Rs706.52 | Rs3370.50 | x |
| 2016-12-31 | Rs753.61 | Rs3370.50 | x |
| 2017-12-31 | Rs879.87 | Rs3370.50 | x |
| 2018-12-31 | Rs963.59 | Rs3370.50 | x |
| 2019-12-31 | Rs1060.46 | Rs3370.50 | x |
| 2020-12-31 | Rs920.08 | Rs3370.50 | x |
| 2021-12-31 | Rs966.37 | Rs3370.50 | x |
| 2022-12-31 | Rs553.96 | Rs3370.50 | x |
| 2023-12-31 | Rs440.80 | Rs3370.50 | x |
| 2024-12-31 | Rs373.68 | Rs3370.50 | x |
| 2025-12-31 | Rs325.30 | Rs3370.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sanofi India Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 43.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.78%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 1.67x
- Recent ROE (43.61%) is above the historical average (26.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 35.20% | 20.20% | 1.29x | 1.35x | Rs1.06 Billion |
| 2005 | 27.70% | 17.96% | 1.16x | 1.33x | Rs927.05 Million |
| 2006 | 27.83% | 19.15% | 1.03x | 1.41x | Rs1.08 Billion |
| 2007 | 20.43% | 16.53% | 0.95x | 1.30x | Rs737.39 Million |
| 2008 | 20.05% | 16.90% | 0.92x | 1.28x | Rs832.89 Million |
| 2009 | 16.89% | 16.15% | 0.81x | 1.29x | Rs642.35 Million |
| 2010 | 15.29% | 14.29% | 0.77x | 1.39x | Rs536.00 Million |
| 2011 | 17.12% | 15.55% | 0.82x | 1.35x | Rs795.26 Million |
| 2012 | 14.67% | 11.23% | 0.96x | 1.35x | Rs562.48 Million |
| 2013 | 19.69% | 14.66% | 0.98x | 1.37x | Rs1.31 Billion |
| 2014 | 17.74% | 13.33% | 0.89x | 1.50x | Rs1.15 Billion |
| 2015 | 19.76% | 14.66% | 0.91x | 1.48x | Rs1.59 Billion |
| 2016 | 17.53% | 12.85% | 0.93x | 1.46x | Rs1.31 Billion |
| 2017 | 16.09% | 13.23% | 0.89x | 1.37x | Rs1.23 Billion |
| 2018 | 17.15% | 13.74% | 0.93x | 1.34x | Rs1.59 Billion |
| 2019 | 16.96% | 13.49% | 0.95x | 1.33x | Rs1.70 Billion |
| 2020 | 22.54% | 16.46% | 0.99x | 1.38x | Rs2.66 Billion |
| 2021 | 42.43% | 31.94% | 0.97x | 1.38x | Rs7.22 Billion |
| 2022 | 48.64% | 22.40% | 1.34x | 1.62x | Rs4.93 Billion |
| 2023 | 59.39% | 30.20% | 1.16x | 1.69x | Rs5.01 Billion |
| 2024 | 48.02% | 20.53% | 1.25x | 1.87x | Rs3.27 Billion |
| 2025 | 43.61% | 17.78% | 1.46x | 1.67x | Rs2.52 Billion |
Industry Comparison
This section compares Sanofi India Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $11,502,409,652
- Average return on equity (ROE) among peers: 24.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sanofi India Limited (SANOFI) | Rs7.49 Billion | 35.20% | 0.67x | $839.48 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $20.07 Billion | 16.78% | 0.50x | $4.15 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $3.29 Billion | 14.62% | 0.66x | $203.47 Million |
| Pfizer Limited (PFIZER) | $42.03 Billion | 17.19% | 0.17x | $2.25 Billion |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $1.23 Billion |
| SENORES PHARMACEUTICALS L (SENORES) | $365.90 Million | 2.71% | 0.62x | $655.14 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $1.18 Billion | 13.66% | 1.33x | $134.99 Million |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more